|
1
|
Towle MJ, Salvato KA, Budrow J, Wels BF,
Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, et
al: In vitro and in vivo anticancer activities of synthetic
macrocyclic ketone analogues of halichondrin B. Cancer Res.
61:1013–1021. 2001.PubMed/NCBI
|
|
2
|
Jain S and Vahdat LT: Eribulin mesylate.
Clin Cancer Res. 17:6615–6622. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cortes J, O'Shaughnessy J, Loesch D, Blum
JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V,
Delozier T, et al: Eribulin monotherapy versus treatment of
physician's choice in patients with metastatic breast cancer
(EMBRACE): A phase 3 open-label randomised study. Lancet.
377:914–923. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kaufman PA, Awada A, Twelves C, Yelle L,
Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE and Cortes J: Phase
III open-label randomized study of eribulin mesylate versus
capecitabine in patients with locally advanced or metastatic breast
cancer previously treated with an anthracycline and a taxane. J
Clin Oncol. 33:594–601. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yodying H, Matsuda A, Miyashita M,
Matsumoto S, Sakurazawa N, Yamada M and Uchida E: Prognostic
significance of neutrophil-to-lymphocyte ratio and
platelet-to-lymphocyte ratio in oncologic outcomes of esophageal
cancer: A systematic review and meta-analysis. Ann Surg Oncol.
23:646–654. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tan D, Fu Y, Su Q and Wang H: Prognostic
role of platelet-lymphocyte ratio in colorectal cancer: A
systematic review and meta-analysis. Med (Baltim).
95(e3837)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zheng J, Cai J, Li H, Zeng K, He L, Fu H,
Zhang J, Chen L, Yao J, Zhang Y and Yang Y: Neutrophil to
lymphocyte ratio and platelet to lymphocyte ratio as prognostic
predictors for hepatocellular carcinoma patients with various
treatments: A meta-analysis and systematic review. Cell Physiol
Biochem. 44:967–981. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Prodromidou A, Andreakos P, Kazakos C,
Vlachos DE, Perrea D and Pergialiotis V: The diagnostic efficacy of
platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in
ovarian cancer. Inflamm Res. 66:467–475. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Miyagawa Y, Araki K, Bun A, Ozawa H,
Fujimoto Y, Higuchi T, Nishimukai A, Kira A, Imamura M and Miyoshi
Y: Significant association between low baseline
neutrophil-to-lymphocyte ratio and improved progression-free
survival of patients with locally advanced or metastatic breast
cancer treated with eribulin but not with nab-paclitaxel. Clin
Breast Cancer. 18:400–409. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Miyoshi Y, Yoshimura Y, Saito K, Muramoto
K, Sugawara M, Alexis K, Nomoto K, Nakamura S, Saeki T, Watanabe J,
et al: High absolute lymphocyte counts are associated with longer
overall survival in patients with metastatic breast cancer treated
with eribulin-but not with treatment of physician's choice-in the
EMBRACE study. Breast Cancer. 27:706–715. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Araki K, Ito Y, Fukada I, Kobayashi K,
Miyagawa Y, Imamura M, Kira A, Takatsuka Y, Egawa C, Suwa H, et al:
Predictive impact of absolute lymphocyte counts for
progression-free survival in human epidermal growth factor receptor
2-positive advanced breast cancer treated with pertuzumab and
trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer.
18(982)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Takamizawa S, Shimoi T, Satomi-Tsushita N,
Yazaki S, Okuya T, Kojima Y, Sumiyoshi-Okuma H, Nishikawa T,
Tanioka M, Sudo K, et al: Neutrophil-to-lymphocyte ratio as a
prognostic factor for patients with metastatic or recurrent breast
cancer treated using capecitabine: A retrospective study. BMC
Cancer. 22(64)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Child CG and Turcotte JG: Surgery and
portal hypertension. Major Probl Clin Surg. 1:1–85. 1964.PubMed/NCBI
|
|
14
|
Pugh RN, Murray-Lyon IM, Dawson JL,
Pietroni MC and Williams R: Transection of the oesophagus for
bleeding oesophageal varices. Br J Surg. 60:646–649.
1973.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Johnson PJ, Berhane S, Kagebayashi C,
Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A,
Palmer D, et al: Assessment of liver function in patients with
hepatocellular carcinoma: A new evidence-based approach-the ALBI
grade. J Clin Oncol. 33:550–558. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hiraoka A, Michitaka K, Kumada T, Izumi N,
Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M,
et al: Validation and potential of albumin-bilirubin grade and
prognostication in a nationwide survey of 46,681 hepatocellular
carcinoma patients in Japan: The need for a more detailed
evaluation of hepatic function. Liver Cancer. 6:325–336.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Allison KH, Hammond MEH, Dowsett M,
McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR,
Chavez-MacGregor M, Perlmutter J, et al: Estrogen and progesterone
receptor testing in breast cancer: ASCO/CAP guideline update. J
Clin Oncol. 38:1346–1366. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P,
Hanna W, et al: Human epidermal growth factor receptor 2 testing in
breast cancer: American Society of Clinical Oncology/College of
American Pathologists clinical practice guideline focused update. J
Clin Oncol. 36:2105–2122. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Farshid G, Dhatrak D, Gilhotra A, Koszyca
B and Nolan J: The impact of 2018 ASCO-CAP HER2 testing guidelines
on breast cancer HER2 results. An audit of 2132 consecutive cases
evaluated by immunohistochemistry and in situ hybridization. Mod
Pathol. 33:1783–1790. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li A, Bai Q, Kong H, Zhou S, Lv H, Zhong
S, Li M, Bi R, Zhou X and Yang W: Impact of the updated 2018
American Society of Clinical Oncology/College of American
Pathologists Guideline for Human Epidermal Growth Factor Receptor 2
Testing in Breast Cancer. Arch Pathol Lab Med. 144:1097–1107.
2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Asano Y, Kashiwagi S, Onoda N, Noda S,
Kawajiri H, Takashima T, Ohsawa M, Kitagawa S and Hirakawa K:
Predictive value of neutrophil/lymphocyte ratio for efficacy of
preoperative chemotherapy in triple-negative breast cancer. Ann
Surg Oncol. 23:1104–1110. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Asano Y, Kashiwagi S, Onoda N, Noda S,
Kawajiri H, Takashima T, Ohsawa M, Kitagawa S and Hirakawa K:
Platelet-lymphocyte ratio as a useful predictor of the therapeutic
effect of neoadjuvant chemotherapy in breast cancer. PLoS One.
11(e0153459)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cuello-López J, Fidalgo-Zapata A,
López-Agudelo L and Vásquez-Trespalacios E: Platelet-to-lymphocyte
ratio as a predictive factor of complete pathologic response to
neoadjuvant chemotherapy in breast cancer. PLoS One.
13(e0207224)2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kim J and Bae JS: Tumor-associated
macrophages and neutrophils in tumor microenvironment. Mediators
Inflamm. 2016(6058147)2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hinshaw DC and Shevde LA: The tumor
microenvironment innately modulates cancer progression. Cancer Res.
79:4557–4566. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gysler SM and Drapkin R: Tumor
innervation: Peripheral nerves take control of the tumor
microenvironment. J Clin Invest. 131(e147276)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ueda S, Saeki T, Takeuchi H, Shigekawa T,
Yamane T, Kuji I and Osaki A: In vivo imaging of eribulin-induced
reoxygenation in advanced breast cancer patients: A comparison to
bevacizumab. Br J Cancer. 114:1212–1218. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Goto W, Kashiwagi S, Asano Y, Takada K,
Morisaki T, Fujita H, Takashima T, Ohsawa M, Hirakawa K and Ohira
M: Eribulin promotes antitumor immune responses in patients with
locally advanced or metastatic breast cancer. Anticancer Res.
38:2929–2938. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Halabi S, Kelly WK, Ma H, Zhou H, Solomon
NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, et
al: Meta-analysis evaluating the impact of site of metastasis on
overall survival in men with castration-resistant prostate cancer.
J Clin Oncol. 34:1652–1659. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sasaki A, Nakamura Y, Mishima S, Kawazoe
A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, et al:
Predictive factors for hyperprogressive disease during nivolumab as
anti-PD1 treatment in patients with advanced gastric cancer.
Gastric Cancer. 22:793–802. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA,
Atkins MB, Leming PD, et al: Five-year survival and correlates
among patients with advanced melanoma, renal cell carcinoma, or
non-small cell lung cancer treated with nivolumab. JAMA Oncol.
5:1411–1420. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kumagai S, Koyama S, Itahashi K,
Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono
H, et al: Lactic acid promotes PD-1 expression in regulatory T
cells in highly glycolytic tumor microenvironments. Cancer Cell.
40:201–218.e9. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lee JC, Mehdizadeh S, Smith J, Young A,
Mufazalov IA, Mowery CT, Daud A and Bluestone JA: Regulatory T cell
control of systemic immunity and immunotherapy response in liver
metastasis. Sci Immunol. 5(eaba0759)2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yu J, Green MD, Li S, Sun Y, Journey SN,
Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, et al: Liver
metastasis restrains immunotherapy efficacy via macrophage-mediated
T cell elimination. Nat Med. 27:152–164. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ye L, Liang R, Zhang J, Chen C, Chen X,
Zhang Y, Wang G, Yang Y and Chen G: Postoperative albumin-bilirubin
grade and albumin-bilirubin change predict the outcomes of
hepatocellular carcinoma after hepatectomy. Ann Transl Med.
7(367)2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Demirtas CO, D'Alessio A, Rimassa L,
Sharma R and Pinato DJ: ALBI grade: Evidence for an improved model
for liver functional estimation in patients with hepatocellular
carcinoma. JHEP Rep. 3(100347)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Liu PH, Hsu CY, Hsia CY, Lee YH, Chiou YY,
Huang YH, Lee FY, Lin HC, Hou MC and Huo TI: ALBI and PALBI grade
predict survival for HCC across treatment modalities and BCLC
stages in the MELD Era. J Gastroenterol Hepatol. 32:879–886.
2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhang P, Zong Y, Liu M, Tai Y, Cao Y and
Hu C: Prediction of outcome in breast cancer patients using test
parameters from complete blood count. Mol Clin Oncol. 4:918–924.
2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Stotz M, Liegl-Atzwanger B, Posch F, Mrsic
E, Thalhammer M, Stojakovic T, Bezan A, Pichler M, Gerger A and
Szkandera J: Blood-based biomarkers are associated with disease
recurrence and survival in gastrointestinal stroma tumor patients
after surgical resection. PLoS One. 11(e0159448)2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Ying HQ, Deng QW, He BS, Pan YQ, Wang F,
Sun HL, Chen J, Liu X and Wang SK: The prognostic value of
preoperative NLR, d-NLR, PLR and LMR for predicting clinical
outcome in surgical colorectal cancer patients. Med Oncol.
31(305)2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Deng Q, He B, Liu X, Yue J, Ying H, Pan Y,
Sun H, Chen J, Wang F, Gao T, et al: Prognostic value of
pre-operative inflammatory response biomarkers in gastric cancer
patients and the construction of a predictive model. J Transl Med.
13(66)2015.PubMed/NCBI View Article : Google Scholar
|
